Identification and Basic Management of Bleeding Disorders in Adults

References

1. 1.↵
   1. Acharya SS,
   2. Coughlin A,
   3. Dimichele DM

   . Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004;2:248–56.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Wahlberg T,
   2. Blombäck M,
   3. Hall P,
   4. Axelsson G

   . Application of indicators, predictors and diagnostic indices in coagulation disorders. I. Evaluation of a self-administered questionnaire with binary questions. Methods Inf Med 1980;19:194–200.

   OpenUrlPubMedWeb of Science
3. 3.↵
   1. Hassan AA,
   2. Kroll MH

   . Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program 2005:403–408.
4. 4.↵
   1. Sadler JE,
   2. Rodeghiero F

   , ISTH SSC Subcommittee on von Willebrand Factor. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005;3:775–7.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Rodeghiero F,
   2. Tosetto A,
   3. Abshire T,
   4. et al

   . ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010;8:2063–5.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Tosetto A,
   2. Castaman G,
   3. Plug I,
   4. Rodeghiero F,
   5. Eikenboom J

   . Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost 2011;9:1143–8.

   OpenUrlCrossRefPubMed
7. 7.↵
   ACOG Committee on Practice Bulletins—Gynecology. American College of Obstetricians and Gynecologists. ACOG practice bulletin: management of anovulatory bleeding. Int J Gynaecol Obstet 2001;72:263–71.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Bolton-Maggs PH,
   2. Chalmers EA,
   3. Collins PW,
   4. et al

   . A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603–33.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Girolami A,
   2. Ruzzon E,
   3. Tezza F,
   4. Scandellari R,
   5. Vettore S,
   6. Girolami B

   . Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia 2006;12:345–51.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Inbal A,
    2. Muszbek L

    . Coagulation factor deficiencies and pregnancy loss. Semin Thromb Hemost 2003;29:171–4.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Warner PE,
    2. Critchley HO,
    3. Lumsden MA,
    4. Campbell-Brown M,
    5. Douglas A,
    6. Murray GD

    . Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol 2004;190:1216–23.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Romney G,
    2. Glick M

    . An updated concept of coagulation with clinical implications. J Am Dent Assoc 2009;140:567–74.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. van Herrewegen F,
    2. Meijers JC,
    3. Peters M,
    4. van Ommen CH

    . Clinical practice: the bleeding child. Part II: disorders of secondary hemostasis and fibrinolysis. Eur J Pediatr 2012;171:201–14.

    OpenUrl
14. 14.↵
    1. Van Ommen CH,
    2. Peters M

    . The bleeding child. Part I: primary hemostatic disorders. Eur J Pediatr 2012;171:1–10.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Cattaneo M

    . Inherited platelet-based bleeding disorders. J Thromb Haemost 2003;1:1628–36.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Cines DB,
    2. Bussel JB,
    3. McMillan RB,
    4. Zehnder JL

    . Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program 2005:390–406.
17. 17.↵
    1. Balduini CL,
    2. Pecci A,
    3. Noris P

    . Inherited thrombocytopenias. The evolving spectrum. Hamostaseologie 2012;32:259–70.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Noris P,
    2. Pecci A,
    3. Di Bari F,
    4. et al

    . Application of a diagnostic algorithm for inherited thrombocytopenias to 46 consecutive patients. Haematologica 2004;89:1219–25.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Balduini CL,
    2. Cattaneo M,
    3. Fabris F,
    4. et al

    . Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica 2003;88:582–92.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Konkle BA

    . Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program 2011:391–6.
21. 21.↵
    1. Coppola A,
    2. Di Minno G

    . Desmopressin in inherited disorders of platelet function. Haemophilia 2008;14(Suppl 1):31–9.

    OpenUrlPubMed
22. 22.↵
    1. Tuohy E,
    2. Litt E,
    3. Alikhan R

    . Treatment of patients with von Willebrand disease. J Blood Med 2011;2:49–57.

    OpenUrlPubMed
23. 23.↵
    1. Nichols WL,
    2. Hultin MB,
    3. James AH,
    4. et al

    . von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14:171–232.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Lee CA,
    2. Chi C,
    3. Pavord SR,
    4. et al

    . The obstetric and gynaecological management of women with inherited bleeding disorders–review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. Haemophilia 2006;12:301–36.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. James AH,
    2. Kouides PA,
    3. Abdul-Kadir R,
    4. et al

    . Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol 2011;158:124–34.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Holland L,
    2. Sarode R

    . Should plasma be transfused prophylactically before invasive procedures? Curr Opin Hematol 2006;13:447–51.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Bushick JB,
    2. Eisenberg JM,
    3. Kinman J,
    4. Cebul RD,
    5. Schwartz JS

    . Pursuit of abnormal coagulation screening tests generates modest hidden preoperative costs. J Gen Intern Med 1989;4:493–7.

    OpenUrlPubMed
28. 28.↵
    1. Hayward CP,
    2. Moffat KA,
    3. Liu Y

    . Laboratory investigations for bleeding disorders. Semin Thromb Hemost 2012;38:742–52.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Kamal AH,
    2. Tefferi A,
    3. Pruthi RK

    . How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007;82:864–73.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Green D

    . Interpreting coagulation assays. Blood Coagul Fibrinolysis. 2010;21(Suppl 1):S3–6.

    OpenUrlPubMed
31. 31.↵
    1. Jones DW,
    2. Gallimore MJ,
    3. Mackie IJ,
    4. Harris SL,
    5. Winter M

    . Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol 2000;110:721–6.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.↵
    1. Mazodier K,
    2. Arnaud L,
    3. Mathian A,
    4. et al

    . Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore) 2012;91:251–60.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Franchini M,
    2. Lippi G

    . Acquired factor VIII inhibitors. Blood 2008;112:250–5.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. Knoebl P,
    2. Marco P,
    3. Baudo F,
    4. et al

    . Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012;10:622–31.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Collins P,
    2. Baudo F,
    3. Huth-Kuhne A,
    4. et al

    . Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010;3:161.

    OpenUrlCrossRefPubMed
36. 36.↵
    1. Huth-Kuhne A,
    2. Baudo F,
    3. Collins P,
    4. et al

    . International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009;94:566–75.

    OpenUrlAbstract/FREE Full Text
37. 37.↵
    1. Tay L,
    2. Duncan E,
    3. Singhal D,
    4. et al

    . Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia. Semin Thromb Hemost 2009;35:769–77.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Zeitler H,
    2. Ulrich-Merzenich G,
    3. Goldmann G,
    4. Vidovic N,
    5. Brackmann HH,
    6. Oldenburg J

    . The relevance of the bleeding severity in the treatment of acquired haemophilia - an update of a single-centre experience with 67 patients. Haemophilia 2010;16:95–101.

    OpenUrlPubMed
39. 39.↵
    1. Hay CRM,
    2. Negrier C,
    3. Ludlam CA

    . The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997;78:1463–7.

    OpenUrlPubMedWeb of Science
40. 40.↵
    1. Morrison AE,
    2. Ludlam CA,
    3. Kessler C

    . Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993;81:1513–20.

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    1. Sekhon SS,
    2. Roy V

    . Thrombocytopenia in adults: a practical approach to evaluation and management. South Med J 2006;99:491–8.

    OpenUrlCrossRefPubMed
42. 42.↵
    1. Drews RE

    . Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med 2003;24:607–22.

    OpenUrlCrossRefPubMedWeb of Science
43. 43.↵
    1. McCrae KR

    . Thrombocytopenia in pregnancy. Hematology Am Soc Hematol Educ Program 2010:397–402.
44. 44.↵
    1. Abildgaard U,
    2. Heimdal K

    . Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol 2013;166:117–23.

    OpenUrlCrossRefPubMed
45. 45.↵
    1. Drews RE,
    2. Weinberger SE

    . Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med 2000;162(2 Pt 1):347–51.

    OpenUrlCrossRefPubMedWeb of Science
46. 46.↵
    1. Mannucci PM,
    2. Peyvandi F

    . TTP and ADAMTS13: when is testing appropriate? Hematology Am Soc Hematol Educ Program 2007:121–6.
47. 47.↵
    1. Stasi R,
    2. Amadori S,
    3. Osborn J,
    4. Newland AC,
    5. Provan D

    . Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med 2006;3:e24.

    OpenUrlCrossRefPubMed
48. 48.↵
    1. Simon TL,
    2. Snyder EL,
    3. Stowell CP,
    4. Strauss RG,
    5. Solheim BG,
    6. Petrides M

    1. Arnold DM,
    2. Smith JW,
    3. Warkentin TE

    . Management of immune thrombocytopenia. In: Simon TL, Snyder EL, Stowell CP, Strauss RG, Solheim BG, Petrides M , eds. Rossi's principles of transfusion medicine. 4th ed. Oxford, UK: Blackwell Publishing Ltd; 2009. p. 344–75.
49. 49.↵
    1. Peterson P,
    2. Hayes TE,
    3. Arkin CF,
    4. et al

    . The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998;133:134–9.

    OpenUrlCrossRefPubMedWeb of Science
50. 50.↵
    1. Castaman G,
    2. Tosetto A,
    3. Goodeve A,
    4. et al

    . The impact of bleeding history, von Willebrand factor and PFA-100(®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. Br J Haematol 2010;151:245–51.

    OpenUrlCrossRefPubMed
51. 51.↵
    1. Sladky JL,
    2. Klima J,
    3. Grooms L,
    4. Kerlin BA,
    5. O'Brien SH

    . The PFA-100® does not predict delta-granule platelet storage pool deficiencies. Haemophilia 2012;18:626–9.

    OpenUrlCrossRefPubMed
52. 52.↵
    1. Akin M,
    2. Polat Y

    . Platelet function analyser (PFA)-100(®) closure time in the evaluation of non-steroidal anti-inflammatory drug-induced platelet dysfunction in children with bleeding symptoms. Blood Transfus 2012;10:545–6.

    OpenUrlPubMed
53. 53.↵
    1. Jámbor C,
    2. von Pape KW,
    3. Spannagl M,
    4. Dietrich W,
    5. Giebl A,
    6. Weisser H

    . Multiple electrode whole blood aggregometry, PFA-100, and in vivo bleeding time for the point-of-care assessment of aspirin-induced platelet dysfunction in the preoperative setting. Anesth Analg 2011;113:31–9.

    OpenUrlCrossRefPubMed
54. 54.↵
    1. Sokkary NA,
    2. Venkateswaran L,
    3. Dietrich JE,
    4. Teruya J

    . Platelet function disorders and menorrhagia in adolescents: a review of laboratory diagnosis. J Pediatri Adolesc Gynecol 2012;25:233–7.

    OpenUrl
55. 55.↵
    1. Favaloro EJ

    . The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. Semin Thromb Hemost 2006;32:537–45.

    OpenUrlCrossRefPubMedWeb of Science
56. 56.↵
    1. Brown DL

    . Congenital bleeding disorders. Curr Probl Pediatr Adolesc Health Care 2005;35:38–62.

    OpenUrlCrossRefPubMed
57. 57.↵
    1. Carpenter SL,
    2. Mathew P

    . Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 2008;14:1250–4.

    OpenUrlCrossRefPubMedWeb of Science
58. 58.↵
    1. Jackson SC,
    2. Odiaman L,
    3. Card RT,
    4. van der Bom JG,
    5. Poon MC

    . Suspected collagen disorders in the bleeding disorder clinic: a case-control study. Haemophilia 2013;19:246–50.

    OpenUrlPubMed
59. 59.↵
    1. Karimi M,
    2. Bereczky Z,
    3. Cohan N,
    4. Muszbek L

    . Factor XIII deficiency. Semin Thromb Hemost 2009;35:426–38.

    OpenUrlCrossRefPubMed
60. 60.↵
    1. Mehta R,
    2. Shapiro AD

    . Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008;14:1255–60.

    OpenUrlCrossRefPubMedWeb of Science
61. 61.↵
    1. Daniele F,
    2. Rossi V,
    3. Santoro C

    . Effective management of intracranial haemorrhage with continuous infusion of highly purified von Willebrand factor/factor VIII complex concentrate in an adult with severe haemophilia A. Blood Transfus 2011;9:472–4.

    OpenUrlPubMed
62. 62.↵
    1. Kalsi H,
    2. Nanayakkara L,
    3. Pasi KJ,
    4. Bowles L,
    5. Hart DP

    . Access to primary dental care for patients with inherited bleeding disorders. Haemophilia 2012;18:510–5.

    OpenUrlPubMed
63. 63.↵
    1. Kumar JN,
    2. Kumar RA,
    3. Varadarajan R,
    4. Sharma N

    . Specialty dentistry for the hemophiliac: is there a protocol in place? Indian J Dent Res 2007;18:48–54.

    OpenUrlCrossRefPubMed
64. 64.↵
    1. Fogarty PF,
    2. Kouides P

    . How we treat: patients with haemophilia undergoing screening colonoscopy. Haemophilia 2010;16:363–5.

    OpenUrlPubMed
65. 65.↵
    1. Brewer A,
    2. Correa ME

    . Guidelines for dental treatment of patients with inherited bleeding disorders. Montreal, Quebec, Canada: World Federation of Hemophilia Dental Committee; 2006. Available from: http://www1.wfh.org/publication/files/pdf-1190.pdf. Accessed May 16, 2014.
66. 66.↵
    1. Hewson I,
    2. Makhmalbaf P,
    3. Street A,
    4. McCarthy P,
    5. Walsh M

    . Dental surgery with minimal factor support in the inherited bleeding disorder population at the Alfred Hospital. Haemophilia 2011;17:e185–8.

    OpenUrlPubMed
67. 67.↵
    1. Lee AP,
    2. Boyle CA,
    3. Savidge GF,
    4. Fiske J

    . Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. Br Dent J 2005;198:33–8, discussion 26.

    OpenUrlCrossRefPubMed
68. 68.↵
    1. Seligsohn U

    . Treatment of inherited platelet disorders. Haemophilia 2012;18(Suppl 4):161–5.

    OpenUrlCrossRefPubMed
69. 69.↵
    1. Liumbruno G,
    2. Bennardello F,
    3. Lattanzio A,
    4. Piccoli P,
    5. Rossetti G

    ; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Work Group. Recommendations for the transfusion of plasma and platelets. Blood Transfus 2009;7:132–50.

    OpenUrlPubMed
70. 70.↵
    British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003;122:10–23.

    OpenUrlCrossRefPubMedWeb of Science
71. 71.↵
    1. Lisman T,
    2. Porte RJ

    . Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010;116:878–85.

    OpenUrlAbstract/FREE Full Text
72. 72.↵
    1. O'Shaughnessy DF,
    2. Atterbury C,
    3. Bolton Maggs P,
    4. et al

    . Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126:11–28.

    OpenUrlCrossRefPubMedWeb of Science
73. 73.↵
    1. Peyvandi F,
    2. Palla R,
    3. Menegatti M,
    4. Mannucci PM

    . Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. Semin Thromb Hemost 2009;35:349–55.

    OpenUrlCrossRefPubMed
74. 74.↵
    1. Rodgers GM

    . Prothrombin complex concentrates in emergency bleeding disorders. Am J Hematol 2012;87:898–902.

    OpenUrlCrossRefPubMed
75. 75.↵
    United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003;9:1–23.

    OpenUrlPubMed
76. 76.↵
    1. Bolton-Maggs PH,
    2. Perry DJ,
    3. Chalmers EA,
    4. et al

    . The rare coagulation disorders–review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004;10:593–628.

    OpenUrlCrossRefPubMedWeb of Science
77. 77.↵
    1. Baudo F,
    2. Collins P,
    3. Huth-Kühne A,
    4. et al

    . Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012;120:39–46.

    OpenUrlAbstract/FREE Full Text
78. 78.↵
    1. De Bels D,
    2. Demeere JL,
    3. Dugauqier J,
    4. Louis P,
    5. Van der Vorst E

    . Continuous infusion of factor VIIIc during heart surgery in a patient with haemophilia A. Eur J Anaesthesiol 2004;21:984–6.

    OpenUrlPubMed
79. 79.↵
    1. Ker K,
    2. Edwards P,
    3. Perel P,
    4. Shakur H,
    5. Roberts I

    . Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012;344:e3054.

    OpenUrlAbstract/FREE Full Text
80. 80.↵
    1. Kouides PA,
    2. Byams VR,
    3. Philipp CS,
    4. et al

    . Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009;145:212–20.

    OpenUrlCrossRefPubMedWeb of Science
81. 81.↵
    1. Krakow EF,
    2. Walker I,
    3. Lamy A,
    4. Anderson JA

    . Cardiac surgery in patients with haemophilia B: a case report and review of the literature. Haemophilia 2009;15:108–13.

    OpenUrlCrossRefPubMedWeb of Science
82. 82.↵
    1. Lin PC,
    2. Hsu CH,
    3. Huang CC,
    4. Chen WS,
    5. Wang JW

    . The blood-saving effect of tranexamic acid in minimally invasive total knee replacement: is an additional pre-operative injection effective? J Bone Joint Surg Br 2012;94:932–6.

    OpenUrlPubMed
83. 83.↵
    1. Nurden AT,
    2. Freson K,
    3. Seligsohn U

    . Inherited platelet disorders. Haemophilia 2012;18(Suppl 4):154–60.

    OpenUrlCrossRefPubMed
84. 84.↵
    1. Tang M,
    2. Wierup P,
    3. Terp K,
    4. Ingerslev J,
    5. Sorensen B

    . Cardiac surgery in patients with haemophilia. Haemophilia 2009;15:101–7.

    OpenUrlCrossRefPubMedWeb of Science
85. 85.↵
    1. Venkateswaran L,
    2. Yee DL

    . Rare bleeding disorders in young women. J Pediatr Adolesc Gynecol 2010;23(6 Suppl):S38–42.

    OpenUrlCrossRefPubMed
86. 86.↵
    1. Yang ZG,
    2. Chen WP,
    3. Wu LD

    . Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Br 2012;94:1153–9.

    OpenUrl
87. 87.↵
    1. Dunn AL,
    2. Cox Gill J

    . Adenotonsillectomy in patients with desmopressin responsive mild bleeding disorders: a review of the literature. Haemophilia 2010;16:711–6.

    OpenUrlCrossRefPubMedWeb of Science
88. 88.↵
    1. Hedges SJ,
    2. Dehoney SB,
    3. Hooper JS,
    4. Amanzadeh J,
    5. Busti AJ

    . Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007;3:138–53.

    OpenUrlCrossRefPubMedWeb of Science
89. 89.↵
    1. Mannucci PM

    . Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90:2515–21.

    OpenUrlFREE Full Text
90. 90.↵
    1. Mannucci PM

    . How I treat patients with von Willebrand disease. Blood 2001;97:1915–9.

    OpenUrlAbstract/FREE Full Text
91. 91.↵
    1. Sanders S,
    2. Purcell S,
    3. Silva M,
    4. Palerme S,
    5. James P

    . Relationship between diagnosis and intervention in women with inherited bleeding disorders and menorrhagia. Haemophilia 2012;18:e273–6.

    OpenUrlPubMed
92. 92.↵
    1. Crowther MA,
    2. Douketis JD,
    3. Schnurr T,
    4. et al

    . Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002;137:251–4.

    OpenUrlCrossRefPubMedWeb of Science
93. 93.↵
    1. Lubetsky A,
    2. Yonath H,
    3. Olchovsky D,
    4. Loebstein R,
    5. Halkin H,
    6. Ezra D

    . Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003;163:2469–73.

    OpenUrlCrossRefPubMedWeb of Science
94. 94.↵
    1. Raj G,
    2. Kumar R,
    3. McKinney WP

    . Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999;159:2721–4.

    OpenUrlCrossRefPubMedWeb of Science